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Background
Riociguat, a soluble guanylate cyclase stimulator, is cur-
rently under investigation for the treatment of pulmon-
ary hypertension. The present studies investigated the
influence of omeprazole and AlOH/MgOH on riociguat
absorption and bioavailability.
Methods
The pharmacokinetics of oral, single-dose, immediate-
release riociguat 2.5 mg were characterized in two open-
label, randomized, crossover studies in healthy males. In
the first study, subjects pretreated for 4 days with once-
daily omeprazole 40 mg received co-treatment with ome-
prazole + riociguat or riociguat alone (no pretreatment)
on Day 5 (n = 12). In the second study, subjects received
co-treatment with 10 mL AlOH/MgOH + riociguat or rio-
ciguat alone (n = 12). Pharmacokinetic characteristics
were analyzed assuming log-normally distributed data.
Safety and tolerability were also assessed.
Results
Riociguat bioavailability was decreased by pre- and co-
treatment with omeprazole, with a mean decrease in
Cmax of 35% and a mean decrease in AUC of 26%
(Table 1; Figure 1). Co-treatment with 10 mL AlOH/
MgOH resulted in a mean decrease in Cmax of 56% and
a mean decrease in AUC of 34% (Table 1; Figure 2). In
the riociguat/omeprazole study, adverse events (AEs)
were reported in 4 (33%) subjects receiving riociguat
alone and in 5 (42%) subjects receiving riociguat + ome-
prazole, with no AEs reported during the omeprazole
pretreatment phase. The most commonly reported AEs
were headache (9 events in 8 subjects; 5 drug-related
events) and flushing (3 events in 2 subjects; all drug-related).
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Table 1 Riociguat pharmacokinetic parameters (geometric means and coefficients of variation)
Riociguat/omeprazole study Riociguat/AlOH/MgOH study
Parametera Riociguat 2.5 mg (n=12) Riociguat 2.5 mg + omeprazole (n=12) Riociguat 2.5 mg (n=12) Riociguat 2.5 mg + AlOH/MgOH (n=12)
GM %CV GM %CV GM %CV GM %CV
AUC (µg⋅h/L) 587.9 71.9 432.8 79.8 465.9 68.2 309.6 87.2
Cmax (µg/L) 73.8 26.6 48.1 33.8 80.8 38.4 35.5 57.1
tmax (h) 3.0 – 3.0 – 1.0 – 2.5 –
t1/2 (h) 7.9 46.4 9.0 25.4 5.9 44.4 8.6 53.8
CL/f 4.3 71.9 5.8 79.8 5.4 68.2 8.1 87.2
AUC, area under plasma concentration–time curve; CL/f, total riociguat clearance from plasma; Cmax, maximum riociguat plasma concentration; CV, coefficient of
variation; GM, geometric mean; t1/2, elimination half-life; tmax, time to reach Cmax.
aData are mean except tmax, which is median.
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Figure 1 Riociguat plasma concentrations after a single oral dose of riociguat 2.5 mg with and without pre- and co-treatment with once-daily
omeprazole 40 mg (geometric means, semilogarithmic scale; all subjects valid for pharmacokinetics; n=12). IR, immediate release.
Figure 2 Riociguat plasma concentrations after a single oral dose of riociguat 2.5 mg with and without co-administration of 10 mL AlOH/MgOH
(geometric means, semilogarithmic scale; all subjects valid for pharmacokinetics; n=12).
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In the riociguat/AlOH/MgOH study, AEs were reported in
9 (75%) subjects receiving riociguat alone and in 8 (67%)
subjects receiving riociguat + AlOH/MgOH. The most
commonly reported AEs were headache (12 events in 7 sub-
jects; all drug-related), rhinitis (3 events in 3 subjects; no
drug-related events), nasal congestion (3 events in 2 sub-
jects; 2 drug-related events), and upper abdominal pain
(3 events in 2 subjects; no drug-related events). No serious
AEs were reported in either study and all AEs resolved by
the end of the observation period.
Conclusion
Treatment with riociguat, with or without omeprazole or
AlOH/MgOH, was well tolerated, with a good safety pro-
file. The results confirm the lower bioavailability of rioci-
guat in neutral versus acidic medium as expected from in
vitro data. For co-medication of antacids like AlOH/
MgOH, staggered intake between riociguat and antacid is
practically possible and may be advisable. A general dose
adaptation for patients with co-medication acting on gas-
tric acidity, beyond the dose titration concept for riociguat,
is not recommended.
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